N

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Director, Head of Investigative Toxicology

Translational Research & Bench BiologyPosted on Nov 5
Full-timeBrisbane, CA, USA$240.1k - $281.7k

About the Job

Requirements

  • A PhD in Toxicology, Pharmacology, Molecular Biology, or a closely related life sciences discipline is required.
  • At least 10 years of relevant nonclinical safety, investigative toxicology, or molecular/cellular toxicology experience in the pharmaceutical or biotechnology industry, including direct hands-on laboratory experience with in vitro and/or complex in vitro (MPS) model systems.
  • Demonstrated experience building, validating, and implementing new in vitro assay platforms or laboratory capabilities in an industry setting.
  • Strong working knowledge of mechanisms of drug-induced toxicity and the in vitro tools used to investigate them, including high-content imaging, primary and immortalized cell culture, hepatocyte/cardiomyocyte models, and genotoxicity assays.
  • Ability to translate in vitro data into actionable risk assessments and communicate findings clearly to cross-functional project teams and senior leadership.
  • Experience managing CRO relationships and evaluating build-versus-buy decisions for laboratory capabilities.

Responsibilities

  • Design, establish, and validate an in-house in vitro toxicology testing platform, including assay selection, equipment procurement, protocol development, and standard operating procedures.
  • Develop and implement in vitro toxicology assays using primary and immortalized cell culture, hepatocyte models, and iPSC cardiomyocyte models to screen for cytotoxicity and off-target liabilities.
  • Define the technical roadmap and prioritize which in vitro assays to bring in-house versus source through CRO partners, balancing scientific value, cost, and speed.
  • Own day-to-day lab operations for the function, including equipment maintenance, vendor and reagent management, and data management systems.
  • Serve as the in vitro/investigative toxicology representative on discovery project teams and provide mechanistic insight into target- and modality-related safety findings.
  • Design and interpret investigative studies to elucidate mechanisms of toxicity, including neosubstrate and off-target degradation risk relevant to targeted protein degrader molecules.
  • Partner with DMPK, Pharmacology, and Discovery Biology to integrate in vitro toxicology data into candidate selection, structure-activity relationship (SAR), and lead optimization decisions.
  • Translate in vitro findings into risk assessments and clear recommendations for project teams and research leadership.
  • Hire, mentor, and develop scientific staff as the in vitro toxicology function grows.
  • Represent in vitro/investigative toxicology in Research Leadership meetings and contribute to the broader nonclinical safety strategy.
  • Foster a collaborative, science-driven culture consistent with Nurix’s values.

Desired Qualifications

  • Postdoctoral training.
  • Experience with targeted protein degradation (TPD) or other novel small molecule modalities, including neosubstrate/off-target degradation risk assessment.
  • Experience establishing or scaling a laboratory function within a growing, clinical-stage biotech.
  • Familiarity with New Approach Methodologies (NAMs) and organ-on-chip/microphysiological systems.
  • People management or mentoring experience.
  • A strong publication record in investigative or molecular toxicology.

About the Company

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.

Company size
201-500
Company stage
IPO
Headquarters
Brisbane, CA
Founded
2012

Recently Posted Jobs

Explore more opportunities at Nurix Therapeutics

See more jobs